Crizotinib-Induced Large Bowel Perforation: A Rare Adverse Event

Crizotinib is a tyrosine kinase inhibitor approved for use in the treatment of anaplastic lymphoma kinase positive, advanced non-small cell lung cancer. This targeted therapy improved clinical outcome and prolonged responses. However, potentially serious adverse effects may occur. We report a case of Crizotinib-induced large bowel perforation.